PURPOSE: To evaluate the effectiveness of the Information Technology-Aided Program of Re lapse Prevention in Schizophrenia (ITAREPS). METHODS:Relapse-prone outpatients with schizophrenia or schizoaffective disorder were randomized to the active (n=75) or control group (n=71). In the active arm, according to the protocol, investigators were prompted to increase the antipsychotic dose upon occurrence of a pharmacological inter vention requiring event (PIRE) detected by ITAREPS. RESULTS: Intention-to-treat (ITT) analysis found no between-group difference in the hospitalization-free survival rate at 12 months. However, the trial suffered from high non-adherence of investigators in the active group, with no antipsychotic dose increase in 61% of PIREs. Furthermore, Cox regression analysis showed a 11-fold increased risk of hospitalization in the absence of pharmacological intervention following a PIRE (hazard ratio [HR]=10.8; 95% confidence interval [CI] 1.4-80.0; p=0.002). Therefore, a post-hoc as-treated analysis was performed, which demonstrated a nine-fold reduction in the risk of hospitalization in ITAREPS Algorithm-Adherers (IAAs, n=25) compared with the ITAREPS Non-interventional group (INIs, n=70; Kaplan-Meier survival analysis, HR=0.11, 95% CI 0.05-0.28, p=0.009; number needed to treat [NNT]=4, 95% CI 3-10). A significant difference in favor of the IAA group was seen in the number of inpatient days (p<0.05) and costs (p<0.05). CONCLUSION: Future ITAREPS trials should target the underlying mechanisms that cause low investigator adherence to the program. TRIAL REGISTRATION: Clinical Trials NCT00712660.
RCT Entities:
PURPOSE: To evaluate the effectiveness of the Information Technology-Aided Program of Re lapse Prevention in Schizophrenia (ITAREPS). METHODS: Relapse-prone outpatients with schizophrenia or schizoaffective disorder were randomized to the active (n=75) or control group (n=71). In the active arm, according to the protocol, investigators were prompted to increase the antipsychotic dose upon occurrence of a pharmacological inter vention requiring event (PIRE) detected by ITAREPS. RESULTS: Intention-to-treat (ITT) analysis found no between-group difference in the hospitalization-free survival rate at 12 months. However, the trial suffered from high non-adherence of investigators in the active group, with no antipsychotic dose increase in 61% of PIREs. Furthermore, Cox regression analysis showed a 11-fold increased risk of hospitalization in the absence of pharmacological intervention following a PIRE (hazard ratio [HR]=10.8; 95% confidence interval [CI] 1.4-80.0; p=0.002). Therefore, a post-hoc as-treated analysis was performed, which demonstrated a nine-fold reduction in the risk of hospitalization in ITAREPS Algorithm-Adherers (IAAs, n=25) compared with the ITAREPS Non-interventional group (INIs, n=70; Kaplan-Meier survival analysis, HR=0.11, 95% CI 0.05-0.28, p=0.009; number needed to treat [NNT]=4, 95% CI 3-10). A significant difference in favor of the IAA group was seen in the number of inpatient days (p<0.05) and costs (p<0.05). CONCLUSION: Future ITAREPS trials should target the underlying mechanisms that cause low investigator adherence to the program. TRIAL REGISTRATION: Clinical Trials NCT00712660.
Authors: Cathaleene Macias; Trishan Panch; Yale M Hicks; Jason S Scolnick; David Lyle Weene; Dost Öngür; Bruce M Cohen Journal: Psychiatr Q Date: 2015-12
Authors: Benjamin Buck; Emily Scherer; Rachel Brian; Rui Wang; Weichen Wang; Andrew Campbell; Tanzeem Choudhury; Marta Hauser; John M Kane; Dror Ben-Zeev Journal: Schizophr Res Date: 2019-03-30 Impact factor: 4.939
Authors: Dror Ben-Zeev; Christopher J Brenner; Mark Begale; Jennifer Duffecy; David C Mohr; Kim T Mueser Journal: Schizophr Bull Date: 2014-03-08 Impact factor: 9.306
Authors: Joseph Firth; Jack Cotter; John Torous; Sandra Bucci; Josh A Firth; Alison R Yung Journal: Schizophr Bull Date: 2015-09-22 Impact factor: 9.306
Authors: Lina Gega; Dina Jankovic; Pedro Saramago; David Marshall; Sarah Dawson; Sally Brabyn; Georgios F Nikolaidis; Hollie Melton; Rachel Churchill; Laura Bojke Journal: Health Technol Assess Date: 2022-01 Impact factor: 4.014
Authors: Benjamin Buck; Kevin A Hallgren; Andrew T Campbell; Tanzeem Choudhury; John M Kane; Dror Ben-Zeev Journal: Front Psychiatry Date: 2021-05-31 Impact factor: 4.157